ISC 2018: ARISE II Supports J&J's EmboTrap Stent-Retriever

The International Stroke Conference in Los Angeles featured new data that will support an FDA submission for J&J/Cerenovous' EmboTrap revascularization device. The findings showed a high rate of "first-pass" effectiveness and EmboTrap was successful in creating final substantial reperfusion in 90% of the treated patients.

More from Approvals

More from Policy & Regulation